US2014141009A1PendingUtilityA1

Use of antagonists targeting metallothionein to treat intestinal inflammation

35
Assignee: DE VOS MARTINEPriority: Jul 8, 2011Filed: Jul 9, 2012Published: May 22, 2014
Est. expiryJul 8, 2031(~5 yrs left)· nominal 20-yr term from priority
Inventors:Martine De VosDebby LaukensLindsey DevisscherMichael A. Lynes
A01K 67/0276A01K 2267/0368A01K 2217/075A61K 2039/505A61P 37/06C07K 16/18A01K 2227/105C07K 14/825C07K 2317/76C07K 2317/24A01K 67/0275A01K 2217/052
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Metallothioneins are stress inducible proteins with modulating functions during inflammation. Antagonizing metallothioneins during gut inflammation reduces markers of inflammations and enhances recuperation of intestinal inflammation.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An antagonist targeting metallothionein for use in treating intestinal inflammation wherein said antagonist is an anti-metallothionein antibody or a fragment thereof which specifically binds to said metallothionein. 
     
     
         2 . An antagonist according to  claim 1 , wherein said intestinal inflammation is Crohn's disease, ulcerative colitis, collagenous-, lymphocytic-, ischemic-, diversion- and indeterminate colitis and Behçet's disease in mammals. 
     
     
         3 . An antagonist according to  claim 1 , wherein said antibody is a monoclonal anti-metallothionein antibody. 
     
     
         4 . An antagonist according to  claim 3 , wherein said monoclonal anti-metallothionein antibody is the monoclonal anti-metallothionein antibody clone UC1MT.

Join the waitlist — get patent alerts

Track US2014141009A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.